Excited states in 212Po were populated by alpha transfer using the 208Pb(18O,14C) reaction, and their deexcitation gamma rays were studied with the Euroball array. Several levels were found to decay by a unique E1 transition (Egamma<1 MeV) populating the yrast state with the same spin value. Their lifetimes were measured by the Doppler-shift attenuation method. The values, found in the range 0.1-1.4 ps, lead to very enhanced transitions, B(E1)=2x10(-2)-1x10(-3) W.u. These results are discussed in terms of an alpha-cluster structure which gives rise to states with non-natural-parity values, provided that the composite system cannot rotate collectively, as expected in the "alpha+208Pb" case. Such states due to the oscillatory motion of the alpha-core distance are observed for the first time.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1103/PhysRevLett.104.042701 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Measurement of the intensities of the long-range alpha particles from Po.
Appl Radiat Isot
October 2023
Departamento de Física, Universidad de Extremadura, E-06006, Badajoz, Spain.
Bi partially decays by β populating excited levels of Po. Some of these excited states of Po decay with very low probability by direct alpha-particle emissions instead of a gamma-alpha cascade. This effect was known since the earliest times after the discovery of radioactivity.
View Article and Find Full Text PDFCD46 targeted Pb alpha particle radioimmunotherapy for prostate cancer treatment.
J Exp Clin Cancer Res
March 2023
Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, 22903, USA.
We recently identified CD46 as a novel prostate cancer cell surface antigen that shows lineage independent expression in both adenocarcinoma and small cell neuroendocrine subtypes of metastatic castration resistant prostate cancer (mCRPC), discovered an internalizing human monoclonal antibody YS5 that binds to a tumor selective CD46 epitope, and developed a microtubule inhibitor-based antibody drug conjugate that is in a multi-center phase I trial for mCRPC (NCT03575819). Here we report the development of a novel CD46-targeted alpha therapy based on YS5. We conjugated Pb, an in vivo generator of alpha-emitting Bi and Po, to YS5 through the chelator TCMC to create the radioimmunoconjugate, Pb-TCMC-YS5.
View Article and Find Full Text PDFPb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for Cancer.
Curr Med Chem
February 2021
Viewpoint Molecular Targeting, Inc., Coralville, Iowa 52241, United States.
Receptor-targeted image-guided Radionuclide Therapy (TRT) is increasingly recognized as a promising approach to cancer treatment. In particular, the potential for clinical translation of receptor-targeted alpha-particle therapy is receiving considerable attention as an approach that can improve outcomes for cancer patients. Higher Linear-energy Transfer (LET) of alpha-particles (compared to beta particles) for this purpose results in an increased incidence of double-strand DNA breaks and improved-localized cancer-cell damage.
View Article and Find Full Text PDFDosimetric evaluation of radionuclides for VCAM-1-targeted radionuclide therapy of early brain metastases.
Theranostics
November 2018
CR-UK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, United Kingdom.
Unlabelled: Brain metastases develop frequently in patients with breast cancer, and present a pressing therapeutic challenge. Expression of vascular cell adhesion molecule 1 (VCAM-1) is upregulated on brain endothelial cells during the early stages of metastasis and provides a target for the detection and treatment of early brain metastases. The aim of this study was to use a model of early brain metastasis to evaluate the efficacy of α-emitting radionuclides, Tb, At, Pb, Bi and Ac; β-emitting radionuclides, Y, Tb and Lu; and Auger electron (AE)-emitters Ga, Zr, In and I, for targeted radionuclide therapy (TRT).
View Article and Find Full Text PDFPreliminary Experiments Using a Passive Detector for Measuring Indoor 220Rn Progeny Concentrations with an Aerosol Chamber.
Health Phys
June 2015
*Institute of Radiation Emergency Medicine, Hirosaki University, 66-1 Hon-cho, Hirosaki, Aomori 036-8564, Japan; †Present address: Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan; ‡National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage, Chiba 263-8555, Japan.
This paper describes preliminary experiments using a passive detector for integrating measurements of indoor thoron (²²⁰Rn) progeny concentrations with an aerosol chamber. A solid state nuclear detector (CR-39) covered with a thin aluminum-vaporized polyethylene plate (Mylar film) was used to detect only alpha particles emitted from ²¹²Po due to ²²⁰Rn progeny deposited on the detector surfaces. The initial experiment showed that Mylar film with area density of more than 5 mg cm⁻² was suitable to cut off completely alpha particles of 7.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!